Advertisement

Nontoxic Goiter

  • Steen Joop Bonnema
  • Laszlo Hegedüs
Reference work entry
Part of the Endocrinology book series (ENDOCR)

Abstract

Nontoxic goiter is a common condition related to deficiency in the iodine intake. Other etiological factors include genetic susceptibility, female gender, age, and tobacco smoking. Since the thyroid tissue has preponderance for nodular degeneration, most goiters harbor nodules of different size and texture. In some patients with long-standing goiter, hyperthyroidism will emerge gradually due to functional autonomy of one or more nodules. Although the risk of malignancy in nodular goiter is low in unselected patients, evaluation by thyroid ultrasonography, and by fine-needle aspiration biopsy of nodules with suspicious features, is crucial for determining the nature of the goiter.

In reaching a treatment decision, a range of factors should be taken into account. Asymptomatic patients with a benign goiter most often need no treatment. Thyroid surgery, typically in the form of a hemi- or a total thyroidectomy, can rapidly remove the target tissue and is the treatment of choice if the goiter is very large, if it compromises the upper airways, or if there is suspicion of thyroid malignancy. Specific risks, correlating with goiter size, include vocal cord paralysis and hypoparathyroidism, and these risks increase in cases of reoperation for recurrent goiter.

The noninvasive nature is the major advantage of radioiodine (131I) therapy, resulting in a goiter volume reduction of 35–50% within 2 years. However, a low thyroid 131I uptake (RAIU) is a hindrance for 131I therapy efficacy in some patients. In such cases, recombinant human TSH (rhTSH) stimulation can augment the goiter shrinkage, which reduces the need for additional treatment due to goiter recurrence. Alternatively, rhTSH stimulation allows a reduction of the administered 131I, while achieving a goiter reduction comparable to that obtained by 131I therapy given without rhTSH stimulation.

In selected patients, noninvasive interventional treatment may be an option in solitary thyroid lesions.

Keywords

Goiter Thyroid Nodule Iodine Deficiency Functional Autonomy Quality of Life Neck Compression Thyroid Ultrasound Risk Assessment Fine-Needle Aspiration Biopsy Thyroidectomy Radioiodine Therapy Recombinant Human Thyrotropin Noninvasive Interventional Therapy 

References

  1. Abdel Rahim AA, Ahmed ME, Hassan MA. Respiratory complications after thyroidectomy and the need for tracheostomy in patients with a large goitre. Br J Surg. 1999;86:88–90.PubMedCrossRefPubMedCentralGoogle Scholar
  2. Abdul-Sater L, Henry M, Majdan A, et al. What are thyroidectomy patients really concerned about? Otolaryngol Head Neck Surg. 2011;144:685–90.PubMedCrossRefPubMedCentralGoogle Scholar
  3. Abrahamsen B, Jorgensen HL, Laulund AS, et al. Low serum thyrotropin level and duration of suppression as a predictor of major osteoporotic fractures-the OPENTHYRO register cohort. J Bone Miner Res. 2014;29:2040–50.CrossRefPubMedGoogle Scholar
  4. Aghini-Lombardi F, Antonangeli L, Martino E, et al. The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey. J Clin Endocrinol Metab. 1999;84:561–6.PubMedPubMedCentralGoogle Scholar
  5. al Suliman NN, Ryttov NF, Qvist N, et al. Experience in a specialist thyroid surgery unit: a demographic study, surgical complications, and outcome. Eur J Surg. 1997;163:13–20.Google Scholar
  6. Albareda M, Viguera J, Santiveri C, et al. Upper airway obstruction in patients with endothoracic goiter enlargement: no relationship between flow-volume loops and radiological tests. Eur J Endocrinol. 2010;163:665–9.PubMedCrossRefPubMedCentralGoogle Scholar
  7. Bahn RS, Burch HB, Cooper DS, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21:593–646.CrossRefGoogle Scholar
  8. Baloch ZW, LiVolsi VA. Current role and value of fine-needle aspiration in nodular goitre. Best Pract Res Clin Endocrinol Metab. 2014;28:531–44.PubMedCrossRefPubMedCentralGoogle Scholar
  9. Berg G, Jacobsson L, Nystrom E, et al. Consequences of inadvertent radioiodine treatment of Graves’ disease and thyroid cancer in undiagnosed pregnancy. Can we rely on routine pregnancy testing? Acta Oncol. 2008;47:145–9.PubMedCrossRefPubMedCentralGoogle Scholar
  10. Berghout A, Wiersinga WM, Drexhage HA, et al. Comparison of placebo with L-thyroxine alone or with carbimazole for treatment of sporadic non-toxic goitre. Lancet. 1990;336:193–7.PubMedCrossRefPubMedCentralGoogle Scholar
  11. Bogazzi F, Tomisti L, Ceccarelli C, et al. Recombinant human TSH as an adjuvant to radioiodine for the treatment of type 1 amiodarone-induced thyrotoxicosis: a cautionary note. Clin Endocrinol. 2010;72:133–4.CrossRefGoogle Scholar
  12. Bone SL, Vertigan AE, Eisenberg RL. Auditory-perceptual voice characteristics in pre-operative patients undergoing thyroid or parathyroid surgery. Folia Phoniatr Logop. 2012;64:87–93.PubMedCrossRefPubMedCentralGoogle Scholar
  13. Bonnema SJ. Upper airway obstruction due to goiter: an overlooked problem! J Postgrad Med. 2008;54:82–3.PubMedCrossRefPubMedCentralGoogle Scholar
  14. Bonnema SJ, Hegedüs L. Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev. 2012;33:920–80.PubMedPubMedCentralCrossRefGoogle Scholar
  15. Bonnema SJ, Bertelsen H, Mortensen J, et al. The feasibility of high dose iodine 131 treatment as an alternative to surgery in patients with a very large goiter: effect on thyroid function and size and pulmonary function. J Clin Endocrinol Metab. 1999;84:3636–41.PubMedPubMedCentralGoogle Scholar
  16. Bonnema SJ, Bennedbæk FN, Wiersinga WM, et al. Management of the nontoxic multinodular goitre: a European questionnaire study. Clin Endocrinol. 2000;53:5–12.CrossRefGoogle Scholar
  17. Bonnema SJ, Andersen PB, Knudsen DU, et al. MR imaging of large multinodular goiters: Observer agreement on volume versus observer disagreement on dimensions of the involved trachea. AJR Am J Roentgenol. 2002a;179:259–66.PubMedCrossRefPubMedCentralGoogle Scholar
  18. Bonnema SJ, Knudsen DU, Bertelsen H, et al. Does radioiodine therapy have an equal effect on substernal and cervical goiter volumes? Evaluation by magnetic resonance imaging. Thyroid. 2002b;12:313–7.PubMedCrossRefPubMedCentralGoogle Scholar
  19. Bonnema SJ, Nielsen VE, Hegedüs L. Long-term effects of radioiodine on thyroid function, size and patient satisfaction in non-toxic diffuse goitre. Eur J Endocrinol. 2004;150:439–45.PubMedCrossRefPubMedCentralGoogle Scholar
  20. Bonnema SJ, Nielsen VE, Boel-Jørgensen H, et al. Improvement of goiter volume reduction after 0.3 mg recombinant human thyrotropin-stimulated radioiodine therapy in patients with a very large goiter: a double-blinded, randomized trial. J Clin Endocrinol Metab. 2007;92:3424–8.PubMedCrossRefPubMedCentralGoogle Scholar
  21. Bonnema SJ, Nielsen VE, Boel-Jørgensen H, et al. Recombinant human thyrotropin-stimulated radioiodine therapy of large nodular goiters facilitates tracheal decompression and improves inspiration. J Clin Endocrinol Metab. 2008;93:3981–4.PubMedCrossRefPubMedCentralGoogle Scholar
  22. Brandt F, Almind D, Christensen K, et al. Excess mortality in hyperthyroidism: the influence of preexisting comorbidity and genetic confounding: a danish nationwide register-based cohort study of twins and singletons. J Clin Endocrinol Metab. 2012;97:4123–9.PubMedPubMedCentralCrossRefGoogle Scholar
  23. Brandt F, Thvilum M, Almind D, et al. Morbidity before and after the diagnosis of hyperthyroidism: a nationwide register-based study. PLoS One. 2013a;8:e66711.PubMedPubMedCentralCrossRefGoogle Scholar
  24. Brandt F, Thvilum M, Almind D, et al. Graves’ disease and toxic nodular goiter are both associated with increased mortality but differ with respect to the cause of death: a Danish population-based register study. Thyroid. 2013b;23:408–13.PubMedCrossRefPubMedCentralGoogle Scholar
  25. Braverman L, Kloos RT, Law Jr B, et al. Evaluation of various doses of recombinant human thyrotropin in patients with multinodular goiters. Endocr Pract. 2008;14:832–9.PubMedCrossRefPubMedCentralGoogle Scholar
  26. Brito JP, Gionfriddo MR, Al NA, et al. The accuracy of thyroid nodule ultrasound to predict thyroid cancer: systematic review and meta-analysis. J Clin Endocrinol Metab. 2014;99:1253–63.PubMedCrossRefPubMedCentralGoogle Scholar
  27. Brix TH, Kyvik KO, Hegedüs L. Major role of genes in the etiology of simple goiter in females: a population-based twin study. J Clin Endocrinol Metab. 1999;84:3071–5.PubMedPubMedCentralGoogle Scholar
  28. Brix TH, Hansen PS, Kyvik KO, et al. Cigarette smoking and risk of clinically overt thyroid disease: a population-based twin case-control study. Arch Intern Med. 2000;160:661–6.PubMedCrossRefPubMedCentralGoogle Scholar
  29. Burikhanov RB, Matsuzaki S. Excess iodine induces apoptosis in the thyroid of goitrogen-pretreated rats in vivo. Thyroid. 2000;10:123–9.PubMedCrossRefPubMedCentralGoogle Scholar
  30. Campanella P, Ianni F, Rota CA, et al. Quantification of cancer risk of each clinical and ultrasonographic suspicious feature of thyroid nodules: a systematic review and meta-analysis. Eur J Endocrinol. 2014;170:R203–11.PubMedCrossRefPubMedCentralGoogle Scholar
  31. Carle A, Krejbjerg A, Laurberg P. Epidemiology of nodular goitre. Influence of iodine intake. Best Pract Res Clin Endocrinol Metab. 2014;28:465–79.PubMedCrossRefPubMedCentralGoogle Scholar
  32. Ceccarelli C, Canale D, Battisti P, et al. Testicular function after 131I therapy for hyperthyroidism. Clin Endocrinol. 2006;65:446–52.CrossRefGoogle Scholar
  33. Choi SH, Kim EK, Kwak JY, et al. Interobserver and intraobserver variations in ultrasound assessment of thyroid nodules. Thyroid. 2010;20:167–72.PubMedPubMedCentralCrossRefGoogle Scholar
  34. Cramon P, Bonnema SJ, Bjorner JB, et al. Quality of life in patients with benign nontoxic goiter: impact of disease and treatment response, and comparison with the general population. Thyroid. 2015;25:284–91.PubMedCrossRefPubMedCentralGoogle Scholar
  35. Dralle H, Machens A, Thanh PN. Minimally invasive compared with conventional thyroidectomy for nodular goitre. Best Pract Res Clin Endocrinol Metab. 2014;28:589–99.PubMedCrossRefPubMedCentralGoogle Scholar
  36. Eng PH, Cardona GR, Fang SL, et al. Escape from the acute Wolff-Chaikoff effect is associated with a decrease in thyroid sodium/iodide symporter messenger ribonucleic acid and protein. Endocrinology. 1999;140:3404–10.PubMedCrossRefPubMedCentralGoogle Scholar
  37. Eszlinger M, Hegedus L, Paschke R. Ruling in or ruling out thyroid malignancy by molecular diagnostics of thyroid nodules. Best Pract Res Clin Endocrinol Metab. 2014;28:545–57.PubMedCrossRefPubMedCentralGoogle Scholar
  38. Fast S, Bonnema SJ, Hegedüs L. The majority of Danish nontoxic goitre patients are ineligible for Levothyroxine suppressive therapy. Clin Endocrinol. 2008;69:653–8.CrossRefGoogle Scholar
  39. Fast S, Nielsen VE, Bonnema SJ, et al. Time to reconsider nonsurgical therapy of benign non-toxic multinodular goitre: focus on recombinant human TSH augmented radioiodine therapy. Eur J Endocrinol. 2009a;160:517–28.PubMedCrossRefPubMedCentralGoogle Scholar
  40. Fast S, Nielsen VE, Grupe P, et al. Optimizing 131I uptake after rhTSH stimulation in patients with nontoxic multinodular goiter: evidence from a prospective, randomized, double-blind study. J Nucl Med. 2009b;50:732–7.PubMedCrossRefPubMedCentralGoogle Scholar
  41. Fast S, Hegedüs L, Grupe P, et al. Recombinant human thyrotropin-stimulated radioiodine therapy of nodular goiter allows major reduction of the radiation burden with retained efficacy. J Clin Endocrinol Metab. 2010a;95:3719–25.PubMedCrossRefPubMedCentralGoogle Scholar
  42. Fast S, Nielsen VE, Bonnema SJ, et al. Dose-dependent acute effects of recombinant human TSH (rhTSH) on thyroid size and function: comparison of 0.1, 0.3 and 0.9 mg of rhTSH. Clin Endocrinol. 2010b;72:411–6.CrossRefGoogle Scholar
  43. Fast S, Nielsen VE, Grupe P, et al. Prestimulation with recombinant human thyrotropin (rhTSH) improves the long-term outcome of radioiodine therapy for multinodular nontoxic goiter. J Clin Endocrinol Metab. 2012;97:2653–60.PubMedCrossRefPubMedCentralGoogle Scholar
  44. Fiore E, Tonacchera M, Vitti P. Influence of iodization programmes on the epidemiology of nodular goitre. Best Pract Res Clin Endocrinol Metab. 2014;28:577–88.PubMedCrossRefPubMedCentralGoogle Scholar
  45. Fiorentino E, Cipolla C, Graceffa G, et al. Local neck symptoms before and after thyroidectomy: a possible correlation with reflux laryngopharyngitis. Eur Arch Otorhinolaryngol. 2011;268:715–20.PubMedCrossRefPubMedCentralGoogle Scholar
  46. Franklyn JA, Maisonneuve P, Sheppard MC, et al. Mortality after the treatment of hyperthyroidism with radioactive iodine. N Engl J Med. 1998;338:712–8.PubMedCrossRefPubMedCentralGoogle Scholar
  47. Franklyn JA, Sheppard MC, Maisonneuve P. Thyroid function and mortality in patients treated for hyperthyroidism. JAMA. 2005;294:71–80.PubMedCrossRefPubMedCentralGoogle Scholar
  48. Garsi JP, Schlumberger M, Rubino C, et al. Therapeutic administration of 131I for differentiated thyroid cancer: radiation dose to ovaries and outcome of pregnancies. J Nucl Med. 2008;49:845–52.PubMedCrossRefPubMedCentralGoogle Scholar
  49. Gharib H, Hegedus L, Pacella CM, et al. Clinical review: nonsurgical, image-guided, minimally invasive therapy for thyroid nodules. J Clin Endocrinol Metab. 2013;98:3949–57.PubMedPubMedCentralCrossRefGoogle Scholar
  50. Gharib H, Papini E, Garber JR, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Associazione Medici Endocrinologi Medical Guidelines for Clinical Practice for the Diagnosis and Management of Thyroid Nodules – 2016 Update. Endocr Pract. 2016;22:622–39.PubMedPubMedCentralCrossRefGoogle Scholar
  51. Giovanella L, Ceriani L, Treglia G. Role of isotope scan, including positron emission tomography/computed tomography, in nodular goitre. Best Pract Res Clin Endocrinol Metab. 2014;28:507–18.PubMedCrossRefPubMedCentralGoogle Scholar
  52. Glinoer D, Verelst J, Ham HR. Abnormalities of esophageal transit in patients with sporadic nontoxic goitre. Eur J Nucl Med. 1987;13:239–43.PubMedCrossRefPubMedCentralGoogle Scholar
  53. Graf H, Fast S, Pacini F, et al. Modified-release recombinant human TSH (MRrhTSH) augments the effect of 131I therapy in benign multinodular goiter. Results from a multicenter international, randomized, placebo-controlled study. J Clin Endocrinol Metab. 2011;96:1368–76.PubMedCrossRefPubMedCentralGoogle Scholar
  54. Grussendorf M, Reiners C, Paschke R, et al. Reduction of thyroid nodule volume by levothyroxine and iodine alone and in combination: a randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2011;96:2786–95.PubMedPubMedCentralCrossRefGoogle Scholar
  55. Hamdan AL, Dowli A, Jabbour J, et al. Phonatory symptoms and impact on quality of life in female patients with goiter. Ear Nose Throat J. 2016;95:E5–E10.PubMedPubMedCentralGoogle Scholar
  56. Hansen PS, Brix TH, Sorensen TI, et al. Major genetic influence on the regulation of the pituitary-thyroid axis: a study of healthy danish twins. J Clin Endocrinol Metab. 2004;89:1181–7.PubMedPubMedCentralCrossRefGoogle Scholar
  57. Hasselgren M, Hegedus L, Godballe C, et al. Benefit of measuring basal serum calcitonin to detect medullary thyroid carcinoma in a Danish population with a high prevalence of thyroid nodules. Head Neck. 2010;32:612–8.PubMedPubMedCentralGoogle Scholar
  58. Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016;26:1–133.PubMedPubMedCentralCrossRefGoogle Scholar
  59. Haymart MR, Repplinger DJ, Leverson GE, et al. Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab. 2008;93:809–14.PubMedCrossRefPubMedCentralGoogle Scholar
  60. Hegedüs L. Thyroid size determined by ultrasound. Influence of physiological factors and non-thyroidal disease (thesis). Dan Med Bull. 1990;37:249–63.PubMedPubMedCentralGoogle Scholar
  61. Hegedüs L. Thyroid ultrasound. Endocrinol Metab Clin N Am. 2001;30:339–60.CrossRefGoogle Scholar
  62. Hegedüs L, Bonnema SJ. Approach to management of the patient with primary or secondary intrathoracic goiter. J Clin Endocrinol Metab. 2010;95:5155–62.PubMedCrossRefPubMedCentralGoogle Scholar
  63. Hegedüs L, Rasmussen N, Ravn V, et al. Independent effects of liver disease and chronic alcoholism on thyroid function and size: the possibility of a toxic effect of alcohol on the thyroid gland. Metabolism. 1988;37:229–33.PubMedCrossRefPubMedCentralGoogle Scholar
  64. Hegedüs L, Nygaard B, Hansen JM. Is routine thyroxine treatment to hinder postoperative recurrence of nontoxic goiter justified? J Clin Endocrinol Metab. 1999;84:756–60.PubMedPubMedCentralGoogle Scholar
  65. Hegedüs L, Bonnema SJ, Bennedbæk FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev. 2003;24:102–32.PubMedCrossRefPubMedCentralGoogle Scholar
  66. Hegedüs L, Brix TH, Paschke R. Etiology of simple goiter. Thyroid. 2009;19:209–11.PubMedCrossRefPubMedCentralGoogle Scholar
  67. Horvath E, Majlis S, Rossi R, et al. An ultrasonogram reporting system for thyroid nodules stratifying cancer risk for clinical management. J Clin Endocrinol Metab. 2009;94:1748–51.PubMedPubMedCentralCrossRefGoogle Scholar
  68. Huysmans DA, Hermus AR, Corstens FH, et al. Large, compressive goiters treated with radioiodine. Ann Intern Med. 1994;121:757–62.PubMedCrossRefPubMedCentralGoogle Scholar
  69. Hyer S, Vini L, O’Connell M, et al. Testicular dose and fertility in men following I(131) therapy for thyroid cancer. Clin Endocrinol. 2002;56:755–8.CrossRefGoogle Scholar
  70. Jarhult J, Vedad R. A conservative approach is reasonable in patients with non-toxic goitre: results from an observational study during 30 years. Eur Thyroid J. 2014;3:240–4.PubMedPubMedCentralGoogle Scholar
  71. Jarløv AE, Hegedüs L, Gjørup T, et al. Observer variation in the clinical assessment of the thyroid gland. J Intern Med. 1991;229:159–61.PubMedCrossRefPubMedCentralGoogle Scholar
  72. Jauregui R, Lilker ES, Bayley A. Upper airway obstruction in euthyroid goiter. JAMA. 1977;238:2163–6.PubMedCrossRefPubMedCentralGoogle Scholar
  73. Jorgensen F, Hesse B, Gronbaek P, et al. Abnormal oesophageal function in patients with non-toxic goiter or enlarged left atrium, demonstrated by radionuclide transit measurements. Scand J Gastroenterol. 1989;24:1186–92.PubMedCrossRefPubMedCentralGoogle Scholar
  74. Kahaly G, Dienes HP, Beyer J, et al. Randomized, double blind, placebo-controlled trial of low dose iodide in endemic goiter. J Clin Endocrinol Metab. 1997;82:4049–53.PubMedCrossRefPubMedCentralGoogle Scholar
  75. Knudsen N, Brix TH. Genetic and non-iodine-related factors in the aetiology of nodular goitre. Best Pract Res Clin Endocrinol Metab. 2014;28:495–506.PubMedCrossRefPubMedCentralGoogle Scholar
  76. Knudsen N, Bülow I, Jørgensen T, et al. Goitre prevalence and thyroid abnormalities at ultrasonography: a comparative epidemiological study in two regions with slightly different iodine status. Clin Endocrinol. 2000;53:479–85.CrossRefGoogle Scholar
  77. Knudsen N, Bülow I, Laurberg P, et al. Alcohol consumption is associated with reduced prevalence of goitre and solitary thyroid nodules. Clin Endocrinol. 2001;55:41–6.CrossRefGoogle Scholar
  78. Knudsen N, Bulow I, Laurberg P, et al. Low goitre prevalence among users of oral contraceptives in a population sample of 3712 women. Clin Endocrinol. 2002;57:71–6.CrossRefGoogle Scholar
  79. Kornelius E, Chiou JY, Yang YS, et al. Iodinated contrast media-induced thyroid dysfunction in euthyroid nodular goiter patients. Thyroid. 2016;26:1030–8.PubMedCrossRefPubMedCentralGoogle Scholar
  80. Krejbjerg A, Bjergved L, Pedersen IB, et al. Thyroid nodules in an 11-year DanThyr follow-up study. J Clin Endocrinol Metab. 2014;99:4749–57.PubMedCrossRefPubMedCentralGoogle Scholar
  81. Lang BH, Chu KK, Tsang RK, et al. Evaluating the incidence, clinical significance and predictors for vocal cord palsy and incidental laryngopharyngeal conditions before elective thyroidectomy: is there a case for routine laryngoscopic examination? World J Surg. 2014;38:385–91.PubMedCrossRefPubMedCentralGoogle Scholar
  82. Laulund AS, Nybo M, Brix TH, et al. Duration of thyroid dysfunction correlates with all-cause mortality. the OPENTHYRO Register Cohort. PLoS One. 2014;9:e110437.PubMedPubMedCentralCrossRefGoogle Scholar
  83. Laurberg P, Jorgensen T, Perrild H, et al. The Danish investigation on iodine intake and thyroid disease, DanThyr: status and perspectives. Eur J Endocrinol. 2006;155:219–28.PubMedCrossRefPubMedCentralGoogle Scholar
  84. Leboulleux S, Tuttle RM, Pacini F, et al. Papillary thyroid microcarcinoma: time to shift from surgery to active surveillance? Lancet Diabetes Endocrinol. 2016;4:933–42.PubMedCrossRefPubMedCentralGoogle Scholar
  85. Lee S, Skelton TS, Zheng F, et al. The biopsy-proven benign thyroid nodule: is long-term follow-up necessary? J Am Coll Surg. 2013;217:81–8.PubMedCrossRefPubMedCentralGoogle Scholar
  86. Melissant CF, Smith SJ, Perlberger R, et al. Lung function, CT-scan and X-ray in upper airway obstruction due to thyroid goitre. Eur Respir J. 1994;7:1782–7.PubMedCrossRefPubMedCentralGoogle Scholar
  87. Menon SK, Jagtap VS, Sarathi V, et al. Prevalence of upper airway obstruction in patients with apparently asymptomatic euthyroid multi nodular goitre. Indian J Endocrinol Metab. 2011;15:S127–31.PubMedPubMedCentralCrossRefGoogle Scholar
  88. Metso S, Jaatinen P, Huhtala H, et al. Increased cardiovascular and cancer mortality after radioiodine treatment for hyperthyroidism. J Clin Endocrinol Metab. 2007;92:2190–6.PubMedCrossRefPubMedCentralGoogle Scholar
  89. Metso S, Auvinen A, Salmi J, et al. Increased long-term cardiovascular morbidity among patients treated with radioactive iodine for hyperthyroidism. Clin Endocrinol. 2008;68:450–7.Google Scholar
  90. Miller MR, Pincock AC, Oates GD, et al. Upper airway obstruction due to goitre: detection, prevalence and results of surgical management. Q J Med. 1990;74:177–88.PubMedPubMedCentralGoogle Scholar
  91. Na DG, Baek JH, Sung JY, et al. Thyroid imaging reporting and data system risk stratification of thyroid nodules: categorization based on solidity and echogenicity. Thyroid. 2016;26:562–72.PubMedCrossRefPubMedCentralGoogle Scholar
  92. Netterville JL, Coleman SC, Smith JC, et al. Management of substernal goiter. Laryngoscope. 1998;108:1611–7.PubMedCrossRefPubMedCentralGoogle Scholar
  93. Nielsen VE, Bonnema SJ, Boel-Jørgensen H, et al. Recombinant human thyrotropin markedly changes the 131I kinetics during 131I therapy of patients with nodular goiter: an evaluation by a randomized double-blinded trial. J Clin Endocrinol Metab. 2005;90:79–83.PubMedCrossRefPubMedCentralGoogle Scholar
  94. Nielsen VE, Bonnema SJ, Boel-Jørgensen H, et al. Stimulation with 0.3-mg recombinant human thyrotropin prior to iodine 131 therapy to improve the size reduction of benign nontoxic nodular goiter: a prospective randomized double-blind trial. Arch Intern Med. 2006;166:1476–82.PubMedCrossRefPubMedCentralGoogle Scholar
  95. Nieuwlaat WA, Hermus AR, Sivro-Prndelj F, et al. Pretreatment with recombinant human TSH changes the regional distribution of radioiodine on thyroid scintigrams of nodular goiters. J Clin Endocrinol Metab. 2001;86:5330–6.PubMedCrossRefPubMedCentralGoogle Scholar
  96. Nieuwlaat WA, Huysmans DA, Van Den Bosch HC, et al. Pretreatment with a single, low dose of recombinant human thyrotropin allows dose reduction of radioiodine therapy in patients with nodular goiter. J Clin Endocrinol Metab. 2003;88:3121–9.PubMedCrossRefPubMedCentralGoogle Scholar
  97. Nieuwlaat WA, Hermus AR, Ross HA, et al. Dosimetry of radioiodine therapy in patients with nodular goiter after pretreatment with a single, low dose of recombinant human thyroid-stimulating hormone. J Nucl Med. 2004;45:626–33.PubMedPubMedCentralGoogle Scholar
  98. Nygaard B, Hegedüs L, Gervil M, et al. Radioiodine treatment of multinodular non-toxic goitre. Br Med J. 1993;307:828–32.CrossRefGoogle Scholar
  99. Nygaard B, Hegedüs L, Gervil M, et al. Influence of compensated radioiodine therapy on thyroid volume and incidence of hypothyroidism in Graves’ disease. J Intern Med. 1995;238:491–7.PubMedCrossRefPubMedCentralGoogle Scholar
  100. Nygaard B, Hegedüs L, Ulriksen P, et al. Radioiodine therapy for multinodular toxic goiter. Arch Intern Med. 1999a;159:1364–8.PubMedCrossRefPubMedCentralGoogle Scholar
  101. Nygaard B, Metcalfe RA, Phipps J, et al. Graves’ disease and thyroid associated ophthalmopathy triggered by 131I treatment of non-toxic goiter. J Endocrinol Investig. 1999b;22:481–5.CrossRefGoogle Scholar
  102. Papini E, Guglielmi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab. 2002;87:1941–6.PubMedPubMedCentralCrossRefGoogle Scholar
  103. Papini E, Pacella CM, Misischi I, et al. The advent of ultrasound-guided ablation techniques in nodular thyroid disease: towards a patient-tailored approach. Best Pract Res Clin Endocrinol Metab. 2014;28:601–18.PubMedPubMedCentralCrossRefGoogle Scholar
  104. Pappalardo G, Guadalaxara A, Frattaroli FM, et al. Total compared with subtotal thyroidectomy in benign nodular disease: personal series and review of published reports. Eur J Surg. 1998;164:501–6.PubMedCrossRefPubMedCentralGoogle Scholar
  105. Pedersen IB, Knudsen N, Perrild H, et al. TSH-receptor antibody measurement for differentiation of hyperthyroidism into Graves’ disease and multinodular toxic goitre: a comparison of two competitive binding assays. Clin Endocrinol. 2001;55:381–90.CrossRefGoogle Scholar
  106. Perrild H, Hansen JM, Hegedüs L, et al. Triiodothyronine and thyroxine treatment of diffuse non-toxic goitre evaluated by ultrasonic scanning. Acta Endocrinol. 1982;100:382–7.PubMedPubMedCentralCrossRefGoogle Scholar
  107. Rago T, Vitti P. Diagnostic role of ultrasound and elastosonography in nodular goiter. Best Pract Res Clin Endocrinol Metab. 2014;28:519–29.PubMedPubMedCentralCrossRefGoogle Scholar
  108. Remonti LR, Kramer CK, Leitão CB, et al. Thyroid ultrasound features and risk of carcinoma: a systematic review and meta-analysis of observational studies. Thyroid. 2015;25:538–50.PubMedPubMedCentralCrossRefGoogle Scholar
  109. Rubio IG, Perone BH, Silva MN, et al. Human recombinant TSH preceding a therapeutic dose of radioiodine for multinodular goiters has no significant effect in the surge of TSH-receptor and TPO antibodies. Thyroid. 2005;15:134–9.PubMedCrossRefPubMedCentralGoogle Scholar
  110. Russ G, Bonnema SJ, Erdogan MF et al. European thyroid association guidelines for ultrasound malignancy risk stratification of thyroid nodules in adults: the EU-TIRADS. Eur Thyroid J. 2017 (in press).Google Scholar
  111. Sawka AM, Lakra DC, Lea J, et al. A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. Clin Endocrinol. 2008a;69:479–90.CrossRefGoogle Scholar
  112. Sawka AM, Lea J, Alshehri B, et al. A systematic review of the gonadal effects of therapeutic radioactive iodine in male thyroid cancer survivors. Clin Endocrinol. 2008b;68:610–7.CrossRefGoogle Scholar
  113. Scerrino G, Inviati A, Di GS, et al. Esophageal motility changes after thyroidectomy; possible associations with postoperative voice and swallowing disorders: preliminary results. Otolaryngol Head Neck Surg. 2013;148:926–32.PubMedCrossRefPubMedCentralGoogle Scholar
  114. Singh ON, Maraka S, Espinosa DA, et al. Diagnostic accuracy of thyroid nodule growth to predict malignancy in thyroid nodules with benign cytology: systematic review and meta-analysis. Clin Endocrinol. 2016;85:122–31.CrossRefGoogle Scholar
  115. Smith TJ, Hegedus L. Graves’ disease. N Engl J Med. 2016;375:1552–65.PubMedPubMedCentralCrossRefGoogle Scholar
  116. Soelberg KK, Bonnema SJ, Brix TH, et al. Risk of malignancy in thyroid incidentalomas detected by 18F-fluorodeoxyglucose positron emission tomography: a systematic review. Thyroid. 2012;22:918–25.PubMedPubMedCentralCrossRefGoogle Scholar
  117. Sørensen JR, Hegedus L, Kruse-Andersen S, et al. The impact of goitre and its treatment on the trachea, airflow, oesophagus and swallowing function. A systematic review. Best Pract Res Clin Endocrinol Metab. 2014;28:481–94.PubMedCrossRefPubMedCentralGoogle Scholar
  118. Surks MI, Ortiz E, Daniels GH, et al. Subclinical thyroid disease: scientific review and guidelines for diagnosis and management. JAMA. 2004;291:228–38.PubMedPubMedCentralCrossRefGoogle Scholar
  119. Swan KZ, Nielsen VE, Bibby BM et al. Is the reproducibility of shear wave elastography of thyroid nodules high enough for clinical use? A methodological study. Clin Endocrinol (Oxf). 2016.  https://doi.org/10.1111/cen.13295. [Epub ahead of print]
  120. Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Ann Intern Med. 1997;126:226–31.PubMedCrossRefPubMedCentralGoogle Scholar
  121. Tan GH, Gharib H, Reading CC. Solitary thyroid nodule. Comparison between palpation and ultrasonography. Arch Intern Med. 1995;155:2418–23.PubMedCrossRefPubMedCentralGoogle Scholar
  122. Thusoo TK, Gupta U, Kochhar K, et al. Upper airway obstruction in patients with goiter studies by flow volume loops and effect of thyroidectomy. World J Surg. 2000;24:1570–2.PubMedCrossRefPubMedCentralGoogle Scholar
  123. Torchio R, Gulotta C, Perboni A, et al. Orthopnea and tidal expiratory flow limitation in patients with euthyroid goiter. Chest. 2003;124:133–40.PubMedCrossRefPubMedCentralGoogle Scholar
  124. Vanderpump MP, Tunbridge WM, French JM, et al. The incidence of thyroid disorders in the community: a twenty-year follow-up of the Whickham Survey. Clin Endocrinol. 1995;43:55–68.CrossRefGoogle Scholar
  125. Vejbjerg P, Knudsen N, Perrild H, et al. Effect of a mandatory iodization program on thyroid gland volume based on individuals’ age, gender, and preceding severity of dietary iodine deficiency: a prospective, population-based study. J Clin Endocrinol Metab. 2007;92:1397–401.PubMedCrossRefPubMedCentralGoogle Scholar
  126. Verloop H, Louwerens M, Schoones JW, et al. Risk of hypothyroidism following hemithyroidectomy: systematic review and meta-analysis of prognostic studies. J Clin Endocrinol Metab. 2012;97:2243–55.PubMedCrossRefPubMedCentralGoogle Scholar
  127. Wallace C, Siminoski K. The Pemberton sign. Ann Intern Med. 1996;125:568–9.PubMedCrossRefPubMedCentralGoogle Scholar
  128. Watt T, Grønvold M, Rasmussen AK, et al. Quality of life in patients with benign thyroid disorders. A review. Eur J Endocrinol. 2006;154:501–10.PubMedCrossRefPubMedCentralGoogle Scholar
  129. Watt T, Cramon P, Frendl DM, et al. Assessing health-related quality of life in patients with benign non-toxic goitre. Best Pract Res Clin Endocrinol Metab. 2014;28:559–75.PubMedCrossRefPubMedCentralGoogle Scholar
  130. Wesche MF, Tiel-Van Buul MM, Lips P, et al. A randomized trial comparing levothyroxine with radioactive iodine in the treatment of sporadic nontoxic goiter. J Clin Endocrinol Metab. 2001;86:998–1005.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of EndocrinologyOdense University HospitalOdenseDenmark
  2. 2.Department of Endocrinology and MetabolismOdense University HospitalOdenseDenmark

Personalised recommendations